The discovery of genotype 16 as the prototype oncogenic human papillomavirus (HPV)
initiated a quarter century of laboratory and epidemiological studies that demonstrated their …

Protein aggregation is one of the key challenges in the development of protein
biotherapeutics. It is a critical product quality issue as well as a potential safety concern due …

The two licensed bivalent and quadrivalent human papillomavirus (HPV) L1 (the major
papillomavirus virion protein) virus-like particle (VLP) vaccines are regarded as safe …

Licensed human papillomavirus (HPV) vaccines contain virus-like particles (VLPs) self-
assembled from L1 major-capsid proteins that are remarkably effective prophylactic …

The amino (N) terminus of the human papillomavirus (HPV) minor capsid protein L2 can
induce low-titer, cross-neutralizing antibodies. The aim of this study was to improve …

Human papillomaviruses (HPVs) are the most common sexually transmitted infections
worldwide. Ninety percent of infected individuals clear the infection within two years; …

Infections with sexually transmitted high-risk Human Papillomavirus (hrHPV), of which there
are at least 15 genotypes, are responsible for a tremendous disease burden by causing …

Although long-term protection is a key-point in evaluating HPV-vaccine over time, there is
currently inadequate information on the duration of HPV vaccine-induced immunity and on …

Human papillomavirus (HPV) is the most common sexually transmitted infection, currently
affecting close to 80 million Americans. Importantly, HPV infection is recognized as the …

Licensed L1-VLP-based immunizations against high-risk mucosal human papillomavirus
(HPV) types have been a great success in reducing anogenital cancers, although they are …